In terms of all cancer rates, cervical cancer ranks seventh, making it a serious global health concern. In Asia, there are 1786,49 million women who are aged 15 or older and are at acute risk of developing cervical cancer. According to estimates from the HPV Information Center, 351,720 women are diagnosed with cervical cancer each year, and 199,902 of them die from this cause. In Asia, cervical cancer affects women more frequently than any other cancer.
With the help of cervical cancer screening, the changes caused by precancerous or cancerous in the cervix can be detected. Routine Pap testing for women over 30 has been advised but the clinical guidelines and risk factors changes. In order to treat precancerous change they need to be detected during the screening.
Due to the high risk of rising cases of cervical cancer, early diagnostic procedures like colposcopy and pelvic tests should be done so that doctors can get a clear idea about the tissues. Pap and HPV tests can be the most relevant and early tests for women. These facilities will increasingly use some of the most advanced methods for diagnosing cervical cancer, which will boost the market's growth.
The Indian government has driven many initiatives for cervical cancer prevention like knowledge about early detection, and needs to have strong R&D from major players on cervical cancer diagnosis and drugs. Gynecologists and nurses get proper guidance and training about this cause and detect it properly. These initiatives also contribute to market expansion. The market is anticipated to expand fruitfully as more potent test-medication combinations are created.
